Physician profile
John Patrick Manta
NPI 1518964832
$1,469.50
in general payments reported to CMS, 2019-2025
23 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $155 · 2021: $149 · 2022: $134 · 2023: $196 · 2024: $101 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $274.15 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $170.85 | 2022-2025 | Gel-One Cross-Linked Hyaluronate |
| Stryker Corporation | $120.13 | 2025 | Axsos |
| Dynasplint Systems INC. | $116.47 | 2019-2023 | Dynasplint |
| Depuy Synthes Sales INC. | $99.16 | 2019-2025 | Monovisc, Orthovisc |
| Amniox Medical, INC. | $96.64 | 2019 | |
| Eclipse Technology Solutions INC. | $82.66 | 2022-2023 | |
| Bioventus LLC | $74.71 | 2021-2023 | Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $57.34 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $52.02 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $47.77 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $38.54 | 2025 | Euflexxa |
| Heraeus Medical, LLC. | $36.00 | 2024 | |
| Medtronic, INC. | $33.45 | 2023 | Catalyft Pl Expandable Interbody System |
| Zyla Life Sciences, INC. | $30.59 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $28.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.33 | 2023 | |
| Davol INC. | $20.41 | 2025 | Arista |
| Solventum Corporation | $17.89 | 2025 | Prevena |
| Ermi LLC | $13.80 | 2020 | |
| Trice Medical, INC. | $13.12 | 2019 | |
| Arteriocyte Medical Systems, INC. | $12.09 | 2019 | |
| Genentech USA, INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Manta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.